Singapore’s TauRx Chief Says Alzheimer’s Disease Candidate May Enter Phase III Trials Soon
This article was originally published in PharmAsia News
Phase III testing is gathering pace on novel drugs targeting tau buildup, the head of Singapore-based TauRx says, adding that the company has enough cash on hand to complete a Phase III study for an Alzheimer’s treatment that has eluded major drug companies focused on amyloids.
You may also be interested in...
Drug fails all primary endpoints in two Phase III studies, following in the footsteps of Pfizer/Janssen’s bapineuzumab. But Lilly points to a secondary signal in pooled data as a sign of some effect on cognitive decline.
Elan’s sole near-term growth prospect is Tysabri after the Irish drug maker spins out its discovery research unit Neotope Biosciences with $120 million to $130 million in start-up capital.
As many observers expected, top-line results from a Phase III study show bapineuzumab doesn’t work in carriers of the ApoE4 gene, who are at highest risk for Alzheimer’s disease. An interim analysis of another Phase III study in carriers will now be “expedited,” and other studies of non-carriers will keep going, Pfizer says.